Severe combined immunodeficiency. A model disease for molecular immunology and therapy - PubMed (original) (raw)
Review
Severe combined immunodeficiency. A model disease for molecular immunology and therapy
Alain Fischer et al. Immunol Rev. 2005 Feb.
Abstract
Severe combined immunodeficiencies (SCIDs) consist of genetically determined arrest of T-cell differentiation. Ten different molecular defects have now been identified, which all lead to early death in the absence of therapy. Transplantation of allogeneic hematopoietic stem cells (HSCT) can restore T-cell development, thus saving the lives of SCID patients. In this review, the different characteristics of HSCT are discussed along with the available data regarding the long-term outcome. Transient thymopoiesis caused by an exhaustion of donor progenitor cells and possibly a progressive loss of thymus function can lead to a progressive decline in T-cell functions. The preliminary results of gene therapy show the correction of two SCID conditions. Based on the assumption that long-lasting pluripotent progenitor cells are transduced, these data suggest that gene therapy could overcome the long-term recurrence of the T-cell immunodeficiency. SCID is thus a disease model for experimental therapy in the hematopoietic system.
Similar articles
- Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J, Zhang F, Giannakopoulos A, Adams S, Fairbanks LD, Gaspar J, Henderson L, Xu-Bayford JH, Davies EG, Veys PA, Kinnon C, Thrasher AJ. Gaspar HB, et al. Mol Ther. 2006 Oct;14(4):505-13. doi: 10.1016/j.ymthe.2006.06.007. Epub 2006 Aug 14. Mol Ther. 2006. PMID: 16905365 - Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. Hacein-Bey-Abina S, et al. N Engl J Med. 2002 Apr 18;346(16):1185-93. doi: 10.1056/NEJMoa012616. N Engl J Med. 2002. PMID: 11961146 Clinical Trial. - Gene therapy of severe combined immunodeficiencies.
Cavazzana-Calvo M, Hacein-Bey S, Yates F, de Villartay JP, Le Deist F, Fischer A. Cavazzana-Calvo M, et al. J Gene Med. 2001 May-Jun;3(3):201-6. doi: 10.1002/1521-2254(200105/06)3:3<201::AID-JGM195>3.0.CO;2-Z. J Gene Med. 2001. PMID: 11437325 Review. - Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us.
Rappeport JM, O'Reilly RJ, Kapoor N, Parkman R. Rappeport JM, et al. Immunol Allergy Clin North Am. 2010 Feb;30(1):17-30. doi: 10.1016/j.iac.2009.10.002. Immunol Allergy Clin North Am. 2010. PMID: 20113884 Review. - Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.
Cowan MJ, Neven B, Cavazanna-Calvo M, Fischer A, Puck J. Cowan MJ, et al. Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):73-5. doi: 10.1016/j.bbmt.2007.10.017. Biol Blood Marrow Transplant. 2008. PMID: 18162224 Review.
Cited by
- Insights into the genetic theory of infectious diseases.
Moundir A, Jeddane L, Bousfiha AA. Moundir A, et al. Tunis Med. 2024 Sep 5;102(9):521-528. doi: 10.62438/tunismed.v102i9.4872. Tunis Med. 2024. PMID: 39287343 Free PMC article. Review. English. - Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases.
Zhang C, Xu J, Wu Y, Xu C, Xu P. Zhang C, et al. Stem Cell Rev Rep. 2024 Aug;20(6):1387-1405. doi: 10.1007/s12015-024-10715-5. Epub 2024 Apr 22. Stem Cell Rev Rep. 2024. PMID: 38644403 Free PMC article. Review. - Generation of inactivated IL2RG and RAG1 monkeys with severe combined immunodeficiency using base editing.
Zheng X, Huang C, Lin Y, Han B, Chen Y, Li C, Li J, Ding Y, Song X, Wang W, Liang W, Wu J, Wu J, Gao J, Wei C, Zhang X, Tu Z, Yan S. Zheng X, et al. Signal Transduct Target Ther. 2023 Sep 4;8(1):327. doi: 10.1038/s41392-023-01544-y. Signal Transduct Target Ther. 2023. PMID: 37661226 Free PMC article. - The application of Interleukin-2 family cytokines in tumor immunotherapy research.
Zhou Y, Quan G, Liu Y, Shi N, Wu Y, Zhang R, Gao X, Luo L. Zhou Y, et al. Front Immunol. 2023 Mar 2;14:1090311. doi: 10.3389/fimmu.2023.1090311. eCollection 2023. Front Immunol. 2023. PMID: 36936961 Free PMC article. Review. - Dysbiosis and primary B-cell immunodeficiencies: current knowledge and future perspective.
Peng Y, Chen Y, Wang Y, Wang W, Qiao S, Lan J, Wang M. Peng Y, et al. Immunol Res. 2023 Aug;71(4):528-536. doi: 10.1007/s12026-023-09365-5. Epub 2023 Mar 18. Immunol Res. 2023. PMID: 36933165 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical